Last $141.99 USD
Change Today -1.33 / -0.93%
Volume 842.7K
PRGO On Other Exchanges
New York
Tel Aviv
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $168.39
52 Week Low
06/5/13 - $112.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company Public Limited Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) primarily in the United States, Israel, the United Kingdom, Mexico, and Australia. Its Consumer Healthcare business offers various OTC and nutrition products, including analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as well as vitamins, dietary supplements, and nutritional drinks. The company’s Nutritionals business develops, manufactures, markets, and distributes infant formula, pediatric nutritionals and vitamins, minerals, and supplements primarily under the Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex brands. Its Rx Pharmaceuticals business develops, manufactures, and markets a portfolio of generic prescription drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, and oral liquids and oral solid dosage forms. The company’s Active Pharmaceutical Ingredients (API) business develops, manufactures, and markets differentiated APIs and finished dosage forms for the branded and generic pharmaceutical industries. In addition, Perrigo Company Public Limited Company is developing TYSABRI for the treatment of multiple sclerosis and crohn’s disease; and ELND005 for the treatment of Alzheimer’s disease and bipolar disorder. Its Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses; and imports other pharmaceutical and medical diagnostic products. The company sells its products to drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. Perrigo Company Public Limited Company was founded in 1887 and is headquartered in Dublin, Ireland.

9,900 Employees
Last Reported Date: 08/15/13
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $526.3K
Executive Vice President of Global Operations...
Total Annual Compensation: $452.5K
Executive Vice President, General Counsel and...
Total Annual Compensation: $452.5K
Executive Vice President and General Manager ...
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2013.

perrigo co plc (PRGO) Key Developments

Perrigo Company to Invest $40 Million to Expand its Facility in Yeruham

Perrigo Company announced that the company will invest $40 million to expand its facility in Yeruham. The Investment Promotion Center has already approved first stage of the plant's expansion to upgrade its production lines, laboratories, and storerooms at a cost of $23 million. The second stage involves construction of a facility. The current plant was built in the 1980s. Perrigo said that the plant expansion was part of a long-term plan to invest ILS 280 million in its Israeli facilities. In addition to the Yeruham plan, the company has a plant for the production of active pharmaceutical ingredients (APIs) in Naot Hovav.

Perrigo Company Announces Launch of Authorized Generic Version of Taclonex Ointment

Perrigo Company plc announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex(R) Ointment (calcipotriene 0.005% /betamethasone dipropionate 0.064%). Taclonex(R) Ointment (calcipotriene 0.005% /betamethasone dipropionate 0.064%) is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older.

Perrigo Company plc Announces partnership with KanPak LLC to Manufacture Store Brand Versions of Ensure(R) Adult Nutritional Drinks

Perrigo Company plc announced that its Nutritionals segment is partnered with KanPak LLC to manufacture store brand adult nutritional drinks comparable to Ensure(R) products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $141.99 USD -1.33

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $57.26 USD -0.44
Forest Laboratories Inc $89.58 USD -0.71
Hospira Inc $42.84 USD -0.16
Mead Johnson Nutrition Co $84.45 USD +0.71
Mylan Inc/PA $46.92 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation PRGO Industry Range
Price/Earnings 53.2x
Price/Sales 3.7x
Price/Book 2.2x
Price/Cash Flow 74.3x
TEV/Sales 4.0x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at